Beigene Ltd
ONC353.920USD
+6.920+1.99%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
36.02BMarktkapitalisierung
575.45KGV TTM
mehr Informationen über Beigene Ltd Unternehmen
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd Informationen
BörsenkürzelONC
Name des UnternehmensBeOne Medicines AG
IPO-datumMar 02, 2016
CEOOyler (John Victor)
Anzahl der mitarbeiter11000
WertpapierartDepository Receipt
GeschäftsjahresendeMar 02
Addressec/o BeOne Medicines I GmbH
StadtBASEL
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
Postleitzahl4051
Telefon41616851900
Websitehttps://beonemedicines.com/
BörsenkürzelONC
IPO-datumMar 02, 2016
CEOOyler (John Victor)
Führungskräfte von Beigene Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
Andere
-1.31B
-92.66%
Nach RegionUSD
Name
Umsatz
Anteil
United States
754.86M
53.45%
China
439.88M
31.15%
Europe
166.58M
11.79%
ROW
50.97M
3.61%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
Andere
-1.31B
-92.66%
Aktionärsstatistik
Aktualisiert: Wed, Jan 14
Aktualisiert: Wed, Jan 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
Andere
62.04%
Aktionäre
Aktionäre
Anteil
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
Andere
62.04%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
17.79%
Corporation
17.28%
Hedge Fund
8.20%
Investment Advisor/Hedge Fund
3.76%
Sovereign Wealth Fund
0.92%
Research Firm
0.57%
Pension Fund
0.05%
Family Office
0.02%
Family Office
0.02%
Andere
51.37%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
581
34.32M
31.29%
-4.58M
2025Q3
565
40.04M
36.51%
-2.11M
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Amgen Inc
18.94M
17.27%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.02%
--
--
Sep 30, 2025
PRIMECAP Management Company
5.08M
4.63%
-7.82K
-0.15%
Sep 30, 2025
Capital International Investors
5.05M
4.6%
+161.05K
+3.30%
Sep 30, 2025
Fidelity Management & Research Company LLC
3.76M
3.43%
+345.36K
+10.12%
Sep 30, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
Sep 30, 2025
Temasek Holdings Pte. Ltd.
1.01M
0.92%
+999.00
+0.10%
Sep 30, 2025
T. Rowe Price International Ltd
941.86K
0.86%
+9.96K
+1.07%
Sep 30, 2025
T. Rowe Price Associates, Inc.
688.71K
0.63%
+600.48K
+680.59%
Sep 30, 2025
Invus Public Equities Advisors, LLC
492.99K
0.45%
-17.00K
-3.33%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
VanEck Biotech ETF
4.03%
First Trust NYSE Arca Biotechnology Index Fund
3.26%
Tema Oncology ETF
2.65%
Global X Aging Population ETF
2.41%
Virtus LifeSci Biotech Products ETF
1.8%
iShares Biotechnology ETF
1.71%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.02%
National Security Emerging Markets Index ETF
0.83%
Capital Group Global Equity ETF
0.79%
Mehr Anzeigen
VanEck Biotech ETF
Anteil4.03%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.26%
Tema Oncology ETF
Anteil2.65%
Global X Aging Population ETF
Anteil2.41%
Virtus LifeSci Biotech Products ETF
Anteil1.8%
iShares Biotechnology ETF
Anteil1.71%
ProShares Ultra Nasdaq Biotechnology
Anteil1.02%
Invesco Nasdaq Biotechnology ETF
Anteil1.02%
National Security Emerging Markets Index ETF
Anteil0.83%
Capital Group Global Equity ETF
Anteil0.79%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
